# Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study

> **NCT05280405** · PHASE4 · UNKNOWN · sponsor: **IRCCS Burlo Garofolo** · enrollment: 86 (estimated)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT05280405
- **Lead sponsor:** IRCCS Burlo Garofolo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-09
- **Primary completion:** 2024-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05280405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05280405, "Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05280405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*